{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T07:05:48Z","timestamp":1672902348343},"reference-count":15,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"abstract":"<jats:p>Although the latest data show that complement activation has an essential role in the pathogenesis and severity of Covid-19, the data on the prognosis of patients using complement inhibitors during Covid-19 infection are scarce. There is no specific treatment for Covid-19 yet. The introduction of novel agents such as favipiravir may affect metabolism of immunosuppressive drugs. We report the clinical course of Covid-19 in a kidney transplant patient with atypical haemolytic uraemic syndrome on chronic eculizumab therapy. The patient had mild Covid-19 but had severe tacrolimus toxicity, which may be associated with favipiravir and eculizumab. The mild course of Covid-19 in our patient is encouraging for eculizumab use; on the other hand, unusually high levels of tacrolimus that we observed underlines the importance of frequent drug level monitoring in transplanted patients who are receiving new drugs.<\/jats:p>","DOI":"10.25259\/nmji_378_21","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:47:29Z","timestamp":1672847249000},"page":"232-234","update-policy":"http:\/\/dx.doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Favipiravir therapy for Covid-19 infection and tacrolimus toxicity in a kidney transplant patient on chronic eculizumab therapy"],"prefix":"10.25259","volume":"35","author":[{"given":"MEVLUT TAMER","family":"DINCER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SINAN","family":"TRABULUS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NURHAN","family":"SEYAHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"10.25259\/NMJI_378_21\/ref-1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","article-title":"Complement as a target in COVID-19?","volume":"20","author":"Risitano","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.25259\/NMJI_378_21\/ref-2","doi-asserted-by":"publisher","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study","volume":"28","author":"Annane","year":"2020","journal-title":"E Clin Med"},{"key":"10.25259\/NMJI_378_21\/ref-3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/RTI.0000000000000524","article-title":"Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology the American College of Radiology, and RSNA-Secondary Publication","volume":"35","author":"Simpson","year":"2020","journal-title":"J Thorac Imaging"},{"key":"10.25259\/NMJI_378_21\/ref-4","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1111\/bjh.16916","article-title":"Terminal complement inhibition dampens the inflammation during COVID-19","volume":"190","author":"Kulasekararaj","year":"2020","journal-title":"Br J Haematol"},{"key":"10.25259\/NMJI_378_21\/ref-5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfaa166","article-title":"Eculizumab, SARSCoV-2 and atypical hemolytic uremic syndrome","volume":"13","author":"Trimarchi","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.25259\/NMJI_378_21\/ref-6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/bjh.17097","article-title":"COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience","volume":"191","author":"Pike","year":"2020","journal-title":"Br J Haematol"},{"key":"10.25259\/NMJI_378_21\/ref-7","doi-asserted-by":"publisher","first-page":"e927418","DOI":"10.12659\/AJCR.927418","article-title":"Mild clinical course of COVID-19 in 3 patients receiving therapeutic monoclonal antibodies targeting C5 complement for hematologic disorders","volume":"21","author":"Araten","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.25259\/NMJI_378_21\/ref-8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2020.1869963","article-title":"Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy","volume":"62","author":"Genthon","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.25259\/NMJI_378_21\/ref-9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","article-title":"The case of complement activation in COVID-19 multiorgan impact","volume":"98","author":"Noris","year":"2020","journal-title":"Kidney Int"},{"key":"10.25259\/NMJI_378_21\/ref-10","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1038\/emi.2015.28","article-title":"The role of C5a in acute lung injury induced by highly pathogenic viral infections","volume":"4","author":"Wang","year":"2015","journal-title":"Emerg Microbes Infect"},{"key":"10.25259\/NMJI_378_21\/ref-11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"key":"10.25259\/NMJI_378_21\/ref-12","doi-asserted-by":"publisher","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: Friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"key":"10.25259\/NMJI_378_21\/ref-13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000512329","article-title":"COVID-19 in renal transplant recipients: Case series and a brief review of current evidence","volume":"145","author":"Elhadedy","year":"2021","journal-title":"Nephron"},{"key":"10.25259\/NMJI_378_21\/ref-14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/17425255.2016.1170808","article-title":"Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: Recent developments and ethnic considerations","volume":"12","author":"Tang","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.25259\/NMJI_378_21\/ref-15","article-title":"Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report","year":"2014"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/favipiravir-therapy-for-covid-19-infection-and-tacrolimus-toxicity-in-a-kidney-transplant-patient-on-chronic-eculizumab-therapy\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/favipiravir-therapy-for-covid-19-infection-and-tacrolimus-toxicity-in-a-kidney-transplant-patient-on-chronic-eculizumab-therapy\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:47:31Z","timestamp":1672847251000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/favipiravir-therapy-for-covid-19-infection-and-tacrolimus-toxicity-in-a-kidney-transplant-patient-on-chronic-eculizumab-therapy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":15,"alternative-id":["10.25259\/NMJI_378_21"],"URL":"https:\/\/doi.org\/10.25259\/nmji_378_21","relation":{},"ISSN":["0970-258X"],"issn-type":[{"value":"0970-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"article-number":"232"}}